In 2023, Baltimore City recorded more than 1,000 drug- and alcohol-related overdose deaths, with fentanyl involved in the overwhelming majority of cases, according to the Baltimore City Health Department. That number makes one thing clear: opioid treatment in Baltimore is not a single decision. It is a series of decisions, each one affecting your odds. This guide breaks down the medications, treatment settings, and insurance realities so you can walk into an intake appointment already knowing what to ask.
Why Baltimore Residents Face Different Odds Depending on Treatment Choice
The Baltimore City Health Department’s 2023 overdose data placed the city among the highest per-capita fentanyl mortality rates of any major American city. But the survival gap between treatment options is just as striking as the overdose statistics themselves. A 2021 analysis published by SAMHSA found that people with opioid use disorder who received medication-assisted treatment were 50 percent less likely to die from an overdose than those who received no medication or detox-only care.
That gap exists because not every approach to opioid treatment delivers equal outcomes. The medication you start on, the setting where you receive care, and whether your provider treats co-occurring mental health conditions all directly affect how long you stay in recovery. This guide compares your options on each of those dimensions so you can make a faster, better-informed choice.
Medication-Assisted Treatment: The Evidence-Based Foundation
A 2021 analysis in the New England Journal of Medicine confirmed what researchers have known for decades: medications that act on opioid receptors reduce overdose mortality, keep people in treatment longer, and outperform abstinence-only approaches across every major outcome measure. What this means in practice is that MAT, the use of FDA-approved medications to reduce cravings and stabilize brain chemistry, is not a workaround or a lesser form of treatment. It is the standard of care for opioid use disorder.
When you evaluate any opioid treatment program in Baltimore, the first question is simple: does this program offer FDA-approved medications as a first-line option? If the answer is no, or if the program requires a detox period before offering medication, that is a clinical red flag. The evidence does not support detox-first approaches for most people dependent on fentanyl or heroin.
Methadone
A 2019 Cochrane review of 31 randomized trials found that methadone was more effective than no medication or placebo at retaining patients in treatment, with significantly higher rates of opioid-negative urine tests. Mechanically, methadone is a long-acting full agonist, meaning it binds fully to opioid receptors and eliminates withdrawal symptoms for 24 to 36 hours. Because of its potency and the risk of diversion, federal law requires that methadone for opioid use disorder be dispensed through a licensed opioid treatment program, or OTP.
In Baltimore, that means daily clinic visits at the start of treatment. Your ability to maintain that schedule, given your work hours, transportation access, and home location, is the key practical variable. Before committing to a methadone program, locate the nearest licensed OTP and confirm their intake hours and take-home dose policy, because some programs allow earned take-home doses after a period of consistent attendance.
Buprenorphine (Suboxone/Subutex)
A 2020 study published in JAMA followed patients who were initiated on buprenorphine in emergency department settings and found a 78 percent retention rate at 30 days compared to 37 percent for referral-only groups. The key clinical advantage buprenorphine holds over methadone for many patients is its flexibility: a licensed provider can prescribe it in an office or telehealth setting, removing the daily clinic requirement entirely.
Buprenorphine is available as a sublingual film (Suboxone combines it with naloxone to deter misuse), a sublingual tablet, or a monthly injectable formulation (Sublocade) for patients who want to remove the daily dosing variable altogether. If you are evaluating a provider, ask directly whether they offer same-day or next-day buprenorphine starts. Research shows that the window between deciding to seek treatment and actually receiving a first dose is one of the highest-risk periods for relapse or overdose. For a closer look at how buprenorphine treatment works in a clinical setting, the patient-focused breakdown of Suboxone treatment in Baltimore covers the intake process in detail.
Naltrexone (Vivitrol)
A 2017 New England Journal of Medicine trial comparing extended-release naltrexone to buprenorphine-naloxone found comparable outcomes in patients who successfully completed detox before starting either medication, but significantly lower treatment entry rates for the naltrexone group because of the detox requirement. Naltrexone is an antagonist, not an agonist. It works by blocking opioid receptors entirely rather than activating them, which means you must be fully detoxed before starting it, typically requiring seven to ten days without opioids.
The clinical implication is direct: naltrexone is the hardest of the three medications to initiate, carries the highest bridge-period relapse risk, and shows lower retention in most head-to-head trials. It is, however, a meaningful option for patients who have already completed medically supervised detox or who are categorically unable to take agonist medications. If a provider recommends naltrexone for you, ask specifically how they manage the detox-to-naltrexone transition, because this gap is where most treatment failures occur.
Treatment Settings: Outpatient, Intensive Outpatient, and Residential
The American Society of Addiction Medicine’s level-of-care criteria, updated in 2023, establish that treatment setting and medication are independent decisions. You can receive buprenorphine in a standard outpatient setting, an intensive outpatient program, or a residential facility. ASAM’s placement criteria, supported by NIH outcome data, show that matching level of care to clinical severity, not defaulting to the most intensive option available, produces better long-term results.
Standard outpatient care typically means one to three visits per week and works well for people with stable housing, strong social support, and moderate severity of use. Intensive outpatient programs, which usually require nine or more hours of structured programming per week, are appropriate for people whose home environment carries significant relapse risk or whose use has been more severe. Residential care makes sense when outpatient attempts have failed or when housing instability makes any outpatient structure unworkable. Before choosing a program, ask which ASAM level of care they are licensed to provide and whether they conduct a formal intake assessment to determine placement, because a program that skips this step is guessing at your needs.
Co-Occurring Mental Health Conditions
SAMHSA’s 2023 National Survey on Drug Use and Health found that more than half of adults with opioid use disorder also met criteria for at least one mental health condition, most commonly depression, anxiety, or PTSD. In Baltimore specifically, where trauma exposure rates are elevated, that overlap is clinically significant.
Programs that treat addiction and mental health in separate silos require you to coordinate two separate care relationships, two separate appointment schedules, and two separate medication regimens, which dramatically increases dropout rates. Integrated programs, where psychiatric evaluation and medication management happen in the same practice, produce significantly better outcomes for this population. When you call any program to ask about intake, ask directly: “Do you have psychiatric prescribers on-site, or do I need a separate referral for mental health treatment?” The answer tells you immediately whether the program is built for patients like you. If you are located outside Baltimore, programs offering mental health-integrated addiction treatment in College Park follow the same integrated model.
Insurance Coverage in Baltimore: What Medicaid Covers and What It Doesn’t
A 2022 KFF analysis found that Maryland was among the states with the strongest Medicaid MAT coverage policies, and subsequent updates have strengthened that further. As of 2023, Maryland Medicaid covers all three FDA-approved MAT medications, including buprenorphine, methadone, and extended-release naltrexone, with no prior authorization requirement for buprenorphine. That policy change removes one of the most common administrative delays that previously kept people from starting treatment quickly.
What this means for you: if you have Maryland Medicaid, cost is not a barrier to starting buprenorphine treatment. The financial obstacle that stopped many Baltimore residents from accessing care a decade ago no longer exists under current state policy. Commercial insurance coverage varies by plan and formulary, and uninsured patients should ask about sliding-scale fees before assuming treatment is out of reach. Call the program’s billing department before your first appointment and ask two specific questions: do you accept Maryland Medicaid, and which MAT medications can you prescribe under that coverage? Getting this answered before intake prevents surprises. If you are comparing what different MAT clinics in Baltimore actually cover, verifying Medicaid acceptance upfront is the fastest way to narrow your list.
The Comparison in Practice: Choosing the Right Option for Your Situation
A 2023 AHRQ comparative effectiveness report on opioid use disorder treatment confirmed that individualized, patient-centered medication matching outperforms protocol-driven approaches. The research supports three clear scenarios.
If you are currently using daily and have not been in treatment before, buprenorphine is the strongest first-line option. It can be started in an office or telehealth visit without prior detox, and same-day initiation is possible at practices set up for it. If you have been through treatment before and relapsed, a longer-acting or injectable formulation of buprenorphine, or a reassessment of your treatment setting, is the right conversation to have. If you have already completed detox and are specifically motivated to use a non-agonist approach, extended-release naltrexone is a viable option with appropriate monitoring. Bring this framing to your intake appointment. Telling a provider which scenario applies to you accelerates the clinical conversation and gets to a prescribing decision faster.
For patients in the Baltimore metro area looking at options across different neighborhoods, finding a provider equipped for same-day evaluation near you is a practical first step before committing to a program.
What to Do This Week
In the next 48 hours, contact a Baltimore-area provider that offers same-day buprenorphine evaluation. In the same call, confirm whether they accept your Medicaid plan or insurance, and ask which medication they recommend given your specific history. That single call collapses this decision from a research project into a scheduled appointment. The evidence on treatment entry is unambiguous: the faster you get from deciding to seeking care, the better your outcome.